Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Patients with extramedullary myeloma (EMM) dx or with solitary plasmacytoma progression have median OS 7.5 years; worse prognosis if with primary or secondary PCL and secondary EMM, high R-ISS, chromosome abnormalities, high LDH.”
Title: Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era
Authors: Megan Broughton, Subodh Bhatta, Doshi Sonali, Naresh Bumma, Abdullah M. Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Francesca Cottini
You can read the Full Article in Haematologica.
More posts featuring Robert Orlowski.
